Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human

• Published in: Alzheimer's & dementia Vol. 16
• Main Authors: Shcherbinin, Sergey, Kielbasa, William, Dubois, Susan, Lowe, Stephen L, Phipps, Krista M, Tseng, James, Kevin, Donnelly B, Natanegara, Fanni, Warner, Susan, Dreyfus, Nicolas, Lindsay‐Scott, Peter, Hawk, Mai Khanh, McDonald, Nicholas, Zhang, Xiaoyu, Gilmore, Julie A, Biglan, Kevin, Mergott, Dustin J, Russell, David, Gunn, Roger N, Constantinescu, Cristian, Nuthall, Hugh Norman, Collins, Emily C
• Format: Journal Article
• Language: English
• Published: 01.12.2020

Background LY3372689, an O‐GlcNAcase (OGA) enzyme inhibitor, is being developed as a potential treatment of tauopathies, including Alzheimer’s disease. OGA inhibition is proposed to delay the progression of tau‐related diseases by slowing the accumulation of hyper‐phosphorylated, insoluble tau filam...